$LENZ Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.32 down -149.06% YoY • Reported revenue of $1.9M • LENZ Therapeutics believes its existing cash, cash equivalents, and marketable securities of $258.4M as of March 31, 2026, are sufficient to fund operations for at least the next 12 months and reach positive operating cash flow.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.